B
Braidwell Portfolio holdings
AUM
$2.92B
This Quarter Return
+4.66%
1 Year Return
-4.59%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$2.98B
AUM Growth
–
Cap. Flow
+$1.69B
Cap. Flow
% of AUM
56.69%
Top 10 Holdings %
Top 10 Hldgs %
33.01%
Holding
88
New
63
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Glaukos
GKOS
|
$72.6M |
| 2 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$71.5M |
| 3 |
Biogen
BIIB
|
$69.9M |
| 4 |
Vaxcyte
PCVX
|
$65.3M |
| 5 |
Natera
NTRA
|
$65.1M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 56.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
DICE
26
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $26.2M | 0.88% |
+839,075
| New | +$26.2M |
|
27
QuidelOrtho
QDEL
$1.87B
| $25.7M | 0.86% |
+300,437
| New | +$25.7M |
|
28
Globus Medical
GMED
$7.94B
| $25.5M | 0.86% |
+343,626
| New | +$25.5M |
|
29
Acadia Pharmaceuticals
ACAD
$4.34B
| $23.8M | 0.8% |
+1,493,121
| New | +$23.8M |
|
30
AnaptysBio
ANAB
$630M
| $22.5M | 0.75% |
+726,122
| New | +$22.5M |
|
|
SILK
31
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $22M | 0.74% |
+416,817
| New | +$22M |
|
32
Esperion Therapeutics
ESPR
$490M
| $21.1M | 0.71% |
+3,393,405
| New | +$21.1M |
|
33
Apellis Pharmaceuticals
APLS
$3.51B
| $20.1M | 0.68% |
+389,596
| New | +$20.1M |
|
34
RAPT Therapeutics
RAPT
$187M
| $19.8M | 0.66% |
+125,000
| New | +$19.8M |
|
|
MRTX
35
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $18.7M | 0.63% |
+413,600
| New | +$18.7M |
|
36
Transmedics
TMDX
$3.65B
| $18.7M | 0.63% |
+303,185
| New | +$18.7M |
|
37
argenx
ARGX
$44.2B
| $18.6M | 0.62% |
+49,200
| New | +$18.6M |
|
|
DBVT
38
DBV Technologies
DBVT
$249M
| $18.5M | 0.62% |
+1,210,779
| New | +$18.5M |
|
39
Sarepta Therapeutics
SRPT
$1.98B
| $18.2M | 0.61% |
+140,352
| New | +$18.2M |
|
40
Replimune Group
REPL
$460M
| $18M | 0.6% |
+662,349
| New | +$18M |
|
41
Steris
STE
$23.9B
| $17.7M | 0.59% |
+95,694
| New | +$17.7M |
|
42
Edwards Lifesciences
EW
$47.7B
| $17.6M | 0.59% |
+235,319
| New | +$17.6M |
|
|
IMGN
43
DELISTED
Immunogen Inc
IMGN
| $17.2M | 0.58% |
+3,474,497
| New | +$17.2M |
|
44
Cooper Companies
COO
$13.3B
| $17.2M | 0.58% |
+208,460
| New | +$17.2M |
|
45
Enanta Pharmaceuticals
ENTA
$189M
| $15.2M | 0.51% |
+325,838
| New | +$15.2M |
|
46
Pulmonx
LUNG
$67.6M
| $13.7M | 0.46% |
+1,621,494
| New | +$13.7M |
|
47
Mersana Therapeutics
MRSN
$34.8M
| $10.9M | 0.37% |
+74,508
| New | +$10.9M |
|
48
Immatics
IMTX
$662M
| $10.9M | 0.36% |
+1,250,052
| New | +$10.9M |
|
49
Protagonist Therapeutics
PTGX
$3.62B
| $10.1M | 0.34% |
+927,800
| New | +$10.1M |
|
50
Viridian Therapeutics
VRDN
$1.59B
| $9.15M | 0.31% |
+313,403
| New | +$9.15M |
|